TY  - JOUR
A1  - Schwerk, Christian
A1  - Papandreou, Thalia
A1  - Schuhmann, Daniel
A1  - Nickol, Laura
A1  - Borkowski, Julia
A1  - Steinmann, Ulrike
A1  - Quednau, Natascha
A1  - Stump, Carolin
A1  - Weiss, Christel
A1  - Berger, Jürgen
A1  - Wolburg, Hartwig
A1  - Claus, Heike
A1  - Vogel, Ulrich
A1  - Ishikawa, Hiroshi
A1  - Tenenbaum, Tobias
A1  - Schroten, Horst
T1  - Polar Invasion and Translocation of Neisseria meningitidis and Streptococcus suis in a Novel Human Model of the Blood-Cerebrospinal Fluid Barrier
JF  - PLoS One
N2  - Acute bacterial meningitis is a life-threatening disease in humans. Discussed as entry sites for pathogens into the brain are the blood-brain and the blood-cerebrospinal fluid barrier (BCSFB). Although human brain microvascular endothelial cells (HBMEC) constitute a well established human in vitro model for the blood-brain barrier, until now no reliable human system presenting the BCSFB has been developed. Here, we describe for the first time a functional human BCSFB model based on human choroid plexus papilloma cells (HIBCPP), which display typical hallmarks of a BCSFB as the expression of junctional proteins and formation of tight junctions, a high electrical resistance and minimal levels of macromolecular flux when grown on transwell filters. Importantly, when challenged with the zoonotic pathogen Streptococcus suis or the human pathogenic bacterium Neisseria meningitidis the HIBCPP show polar bacterial invasion only from the physiologically relevant basolateral side. Meningococcal invasion is attenuated by the presence of a capsule and translocated N. meningitidis form microcolonies on the apical side of HIBCPP opposite of sites of entry. As a functionally relevant human model of the BCSFB the HIBCPP offer a wide range of options for analysis of disease-related mechanisms at the choroid plexus epithelium, especially involving human pathogens.
KW  - gene expression
KW  - plexus epithelial-cells
KW  - central-nervous-system
KW  - microvascular endothelial-cells
KW  - choroid-plexus
KW  - in vitro
KW  - brain barrier
KW  - tight junctions
KW  - meningococcal disease
KW  - bacterial meningitis
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-131459
VL  - 7
IS  - 1
ER  - 
TY  - JOUR
A1  - Hampf, Chantal
A1  - Scherf-Clavel, Maike
A1  - Weiß, Carolin
A1  - Klüpfel, Catherina
A1  - Stonawski, Saskia
A1  - Hommers, Leif
A1  - Lichter, Katharina
A1  - Erhardt-Lehmann, Angelika
A1  - Unterecker, Stefan
A1  - Domschke, Katharina
A1  - Kittel-Schneider, Sarah
A1  - Menke, Andreas
A1  - Deckert, Jürgen
A1  - Weber, Heike
T1  - Effects of anxious depression on antidepressant treatment response
JF  - International Journal of Molecular Sciences
N2  - Anxious depression represents a subtype of major depressive disorder and is associated with increased suicidality, severity, chronicity and lower treatment response. Only a few studies have investigated the differences between anxious depressed (aMDD) and non-anxious depressed (naMDD) patients regarding treatment dosage, serum-concentration and drug-specific treatment response. In our naturalistic and prospective study, we investigated whether the effectiveness of therapy including antidepressants (SSRI, SNRI, NaSSA, tricyclics and combinations) in aMDD patients differs significantly from that in naMDD patients. In a sample of 346 patients, we calculated the anxiety somatization factor (ASF) and defined treatment response as a reduction (≥50%) in the Hamilton Depression Rating Scale (HDRS)-21 score after 7 weeks of pharmacological treatment. We did not observe an association between therapy response and the baseline ASF-scores, or differences in therapy outcomes between aMDD and naMDD patients. However, non-responders had higher ASF-scores, and at week 7 aMDD patients displayed a worse therapy outcome than naMDD patients. In subgroup analyses for different antidepressant drugs, venlafaxine-treated aMDD patients showed a significantly worse outcome at week 7. Future prospective, randomized-controlled studies should address the question of a worse therapy outcome in aMDD patients for different psychopharmaceuticals individually.
KW  - pharmacotherapy
KW  - depressive disorder
KW  - anxious depression
KW  - anxiety
KW  - therapy response
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-355801
SN  - 1422-0067
VL  - 24
IS  - 24
ER  -